ICIs are indicated for use in diverse cancer types and include monoclonal antibodies that target the immune checkpoint proteins programmed death receptor-1 (PD-1), programmed death ligand-1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) [28]. This evidence concerns the gene PDCD1 and cancer.